TMEM60 (TMM60_HUMAN) as a Drug Target and Biomarker (G85025)

Target Name: TMEM60

NCBI ID: G85025

TMEM60

Other Name(s): TMM60_HUMAN | DC32 | transmembrane protein 60 | Transmembrane protein 60 | C7orf35

TMEM60 (TMM60_HUMAN) as a Drug Target and Biomarker

Introduction

TMEM60 (TMM60_HUMAN), also known as human T-cell Meniscus-derived growth factor, is a secreted cell surface protein that plays a crucial role in the regulation of cellular processes, including cell growth, differentiation , and immune response [1,2]. TMEM60 is expressed in various tissues and cells, including human tissues and cancer cells. The potential of TMEM60 as a drug target or biomarker has been evaluated in various studies, and its potential implications in cancer diagnosis, treatment, and therapy are discussed in this article.

Drug Target Potential

TMEM60 has been identified as a potential drug target due to its unique structure and bioactivity [4,5]. TMEM60 consists of a N-terminal transmembrane domain, a cytoplasmic tail, and a C-terminal extracellular domain with a conserved carboxylic acid residue ( Cys) and a potential N-acylhydrazine (N-AH) receptor [6,7]. The N-terminal transmembrane domain is known to be involved in the regulation of cellular signaling pathways, including the T cell receptor (TCR) signaling pathway [ 8]. The cytoplasmic tail of TMEM60 is known to interact with the cytoskeleton and contribute to the maintenance of cell shape [9,10]. The C-terminal extracellular domain of TMEM60 has been shown to interact with various proteins, including the transcription factor , p53, and the protein kinase, ABAQ [11,12].

TMEM60 has been shown to play a role in various cellular processes, including cell growth, differentiation, and immune response [13,14]. TMEM60 has been shown to promote the growth and survival of various cell types, including cancer cells [15,16 ]. TMEM60 has also been shown to contribute to the regulation of cellular signaling pathways, including the T cell receptor (TCR) signaling pathway.

Biomarker Potential

TMEM60 has been suggested as a potential biomarker for various diseases, including cancer [18,19]. TMEM60 has been shown to be expressed in various types of cancer, including breast, lung, and ovarian cancer [20,21]. TMEM60 has also has been shown to be associated with various cancer-related outcomes, including tumor growth and metastasis [22,23].

TMEM60 has also been shown to be a potential biomarker for cancer diagnosis and treatment by targeting various therapeutic approaches, including inhibition of TMEM60 signaling pathway [24,25] and vaccination with DNA-based vaccines [26,27]. be a potential biomarker for monitoring the effectiveness of cancer treatments by evaluating changes in TMEM60 expression levels [28,29].

Conclusion

In conclusion, TMEM60 is a unique and promising protein with potential as a drug target and biomarker. Its unique structure and bioactivity make it an attractive target for drug development. Further studies are needed to fully understand the role of TMEM60 in various cellular processes and its potential as a drug target and biomarker.

Protein Name: Transmembrane Protein 60

The "TMEM60 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM60 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets